IMRX
Immuneering·NASDAQ
--
--(--)
--
--(--)
IMRX fundamentals
Immuneering (IMRX) released its earnings on Nov 12, 2025: revenue was 0 (YoY --), met estimates; EPS was -0.38 (YoY +22.45%), beat estimates.
Revenue / YoY
0
--
EPS / YoY
-0.38
+22.45%
Report date
Nov 12, 2025
IMRX Earnings Call Summary for Q3,2025
- Breakthrough Pancreatic Cancer Data: 86% overall survival at nine months vs. 47% standard care, with complete responses in FOLFIRINOX combo arm.
- $227M Cash Runway: 2029 funding secured for phase 3 trial and lung cancer collaborations.
- Unique Mechanism: Deep cyclic MEK inhibition blocks resistance, no MAPK pathway mutations detected.
- Upcoming Trials: Phase 3 pancreatic cancer start mid-2026; Libtayo lung trial H2 2026; Lilly KRAS G12C combo pending.
EPS
Actual | -1.61 | -0.47 | -0.42 | -0.49 | -0.44 | -0.49 | -0.5 | -0.51 | -0.43 | -0.43 | -0.52 | -0.49 | -0.47 | -0.49 | -0.58 | -0.42 | -0.4 | -0.38 |
Forecast | -1.655 | -0.5625 | -0.386 | -0.4383 | -0.5129 | -0.48 | -0.5614 | -0.5413 | -0.5275 | -0.4888 | -0.4629 | -0.5029 | -0.52 | -0.5519 | -0.416 | -0.5267 | -0.4003 | -0.3883 |
Surprise | +2.72% | +16.44% | -8.81% | -11.80% | +14.21% | -2.08% | +10.94% | +5.78% | +18.48% | +12.03% | -12.34% | +2.57% | +9.62% | +11.22% | -39.42% | +20.26% | +0.07% | +2.14% |
Revenue
Actual | 660.04K | 482.13K | 189.59K | 183.70K | 94.42K | 38.38K | 456 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Forecast | 725.00K | 700.00K | 535.50K | 182.00K | 196.80K | 153.33K | 60.00K | 8.33K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Surprise | -8.96% | -31.12% | -64.60% | +0.93% | -52.02% | -74.97% | -99.24% | -100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Earnings Call
You can ask Aime
What does Immuneering do and what are its main business segments?What is Immuneering's latest dividend and current dividend yield?What guidance did Immuneering's management provide for the next earnings period?What is Immuneering's gross profit margin?What were the key takeaways from Immuneering’s earnings call?What factors drove the changes in Immuneering's revenue and profit?What is the revenue and EPS growth rate for Immuneering year over year?What were the key takeaways from Immuneering's earnings call?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
